LEON yields 11049.72% · ABBV yields 3.12%● Live data
📍 LEON pulled ahead of the other in Year 1
Combined, LEON + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LEON + ABBV for your $10,000?
Leone Asset Management, Inc., through its subsidiaries, provides financial advisory and consulting services in the United States and internationally. Its services comprise consulting, investment banking, asset management, private equity, financial inclusion, and fund management services. The company provides financial advice on individual wealth management, mergers, acquisitions, restructurings, financing, and capital raising primarily to individuals, corporations, partnerships, institutions, and governments. It also operates two alluvial diamond mines in the Bo and Kono regions of Sierra Leone; and exports minerals. In addition, the company provides residential and commercial real estate brokerage services, as well as commercial property management services in Sierra Leone. It operates leonerealty.com, which enables brokers to list residential and commercial properties, as well as allows home buyers or renters search for home. The company was formerly known as Sloud, Inc. and changed its name to Leone Asset Management, Inc. in August 2013. The company is headquartered in Largo, Florida.
Full LEON Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.